drugset / Trial / NCT00955253

Guanfacine for the Treatment of Spatial Neglect and Impaired Vigilance

NCT00955253

Phase 2 Completed 13 enrolled Imperial College London Wellcome Trust · collab
RandomizedCrossoverTriple-blindTreatment

Summary

To find out if spatial neglect following stroke and brain injury can be reduced using guanfacine, a drug that was shown to improve neglect in two stroke patients in a previous pilot study (Malhotra et al, 2006). In this trial, the effects of guanfacine will be examined in a larger number of patients, and there will also be a systematic assessment of whether the drug is only effective in patients with particular patterns of brain damage.

Timeline

Start
2010-04
Primary completion
2014-03-28
Completion
2014-03-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Guanfacine Small molecule 2 mg Oral